IL2 and melanoma: The most advanced product may be represented by a combination of L19-IL2 with L19-TNF, which is currently being investigated in Phase III clinical trials (NCT02938299 and NCT03567889) for the treatment of fully-resectable Stage IIIB, C melanoma (22).